High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study

Faculty Opinions recommendation of High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.723891858.793501469 ◽

2014 ◽

Author(s):

Robert Huddart

Keyword(s):

Poor Prognosis ◽

Phase Ii Study ◽

Germ Cell Tumors ◽

High Dose ◽

Line Treatment ◽

First Line ◽

Sequential Chemotherapy ◽

Randomized Phase Ii ◽

The role of paclitaxel in the first-line treatment of patients with ‘poor prognosis’ germ cell tumor (GCT) undergoing sequential high dose chemotherapy

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.4633 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4633-4633

Author(s):

J. T. Hartmann ◽

O. Rick ◽

M. Thomas ◽

J. Schleicher ◽

B. Metzner ◽

...

Keyword(s):

Germ Cell ◽

Poor Prognosis ◽

High Dose Chemotherapy ◽

Cell Tumor ◽

High Dose ◽

Line Treatment ◽

First Line ◽

The role of paclitaxel in the first-line treatment of patients with ‘poor prognosis’ germ cell tumor (GCT) undergoing sequential high dose chemotherapy

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.4633 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4633-4633

Author(s):

J. T. Hartmann ◽

O. Rick ◽

M. Thomas ◽

J. Schleicher ◽

B. Metzner ◽

...

Keyword(s):

Germ Cell ◽

Poor Prognosis ◽

High Dose Chemotherapy ◽

Cell Tumor ◽

High Dose ◽

Line Treatment ◽

First Line ◽

7100 High-dose sequential chemotherapy versus conventional-dose chemotherapy as first-line treatment for advanced poor prognosis germ-cell tumors: a multicenter Phase III Italian trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71433-8 ◽

2009 ◽

Vol 7 (2) ◽

pp. 422 ◽

Cited By ~ 4

Author(s):

M. Di Nicola ◽

A. Necchi ◽

N. Nicolai ◽

C. Bengala ◽

S. Siena ◽

...

Keyword(s):

Poor Prognosis ◽

Germ Cell Tumors ◽

Phase Iii ◽

High Dose ◽

First Line ◽

Sequential Chemotherapy ◽

Conventional Dose ◽

Multicenter Phase ◽

First Line Treatment ◽

Conventional Dose Chemotherapy

A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma

Cancer ◽

10.1002/cncr.20859 ◽

2005 ◽

Vol 103 (4) ◽

pp. 772-779 ◽

Cited By ~ 9

Author(s):

Filippo De Marinis ◽

Fabrizio Nelli ◽

Marco Lombardo ◽

Francesco Ferraú ◽

Santi Barbera ◽

...

Keyword(s):

Poor Prognosis ◽

Phase Ii Study ◽

Small Cell Lung Carcinoma ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Cell Lung Carcinoma ◽

Randomized Phase Ii ◽

Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)

10.1158/1538-7445.am2014-ct101 ◽

2014 ◽

Cited By ~ 23

Author(s):

Richard S. Finn ◽

John P. Crown ◽

Istvan Lang ◽

Katalin Boer ◽

Igor M. Bondarenko ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Breast ◽

Line Treatment ◽

Cyclin Dependent Kinase ◽

First Line ◽

Randomized Phase Ii ◽

Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G

Annals of Oncology ◽

10.1093/annonc/mdy281.151 ◽

2018 ◽

Vol 29 ◽

pp. viii201

Author(s):

Y. Kito ◽

T. Yamada ◽

T. Matsumoto ◽

H. Yasui ◽

K. Murata ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Cetuximab in combination with methotrexate (MTX) as first-line treatment in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A phase Ib randomized phase II study versus single agent MTX

Annals of Oncology ◽

10.1093/annonc/mdy287.024 ◽

2018 ◽

Vol 29 ◽

pp. viii381

Author(s):

J. Ham ◽

E. Meerten ◽

E. Fiets ◽

F. Jeurissen Mc Haaglanden ◽

M. Slingerland ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii Study ◽

Single Agent ◽

Line Treatment ◽

First Line ◽

Phase Ib ◽

Randomized Phase Ii ◽

A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial

Annals of Oncology ◽

10.1093/annonc/mdx772 ◽

2018 ◽

Vol 29 (3) ◽

pp. 661-668 ◽

Cited By ~ 1

Author(s):

A. Gennari ◽

Z. Sun ◽

U. Hasler-Strub ◽

M. Colleoni ◽

M.J. Kennedy ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Maintenance Schedules ◽

Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.7012 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 7012-7012 ◽

Cited By ~ 43

Author(s):

R. Rosell ◽

C. Daniel ◽

R. Ramlau ◽

A. Szczesna ◽

M. Constenla ◽

...

Keyword(s):

Lung Cancer ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Randomized Phase Ii ◽

Epidermal Growth ◽